SUMMARY Twenty-five adult epileptic patients who had shown a satisfactory clinical response to add-on vigabatrin under placebo-controlled conditions continued on long-term treatment for up to 47 months (median 22 months). The initially favourable therapeutic response was generally maintained throughout the observation period with an overall good clinical tolerance. No evidence of neurotoxicity was detected by multimodal evoked potentials monitoring.
In recent years, the hypothesis that enhancement of GABA-ergic transmission may have important therapeutic effects in epilepsy has received strong experimental support by the demonstration that the GABA-transaminase inhibitor vigabatrin (VGB), which raises brain GABA levels in animals and in man,' is a very effective anticonvulsant in the clinical setting. Short-term placebo-controlled studies have shown consistently that the drug induces a greater than 50% decrease in fit frequency in approximately 60% of patients with otherwise "intractable" seizure disorders.2' In order to assess fully the potential usefulness of VGB in the management of epilepsy, however, its anticonvulsant efficacy and clinical tolerability also need to be evaluated during chronic treatment. In the only long-term study published to date, the investigators from the U.S. Collaborative Multicenter Study7 have recently reported on 66 patients with complex partial seizures maintained on VGB for 4 to 25 months (median 16-7 months); among the 41 patients who had shown a good initial response to the drug, most were found to retain this effect throughout the full treatment period, suggesting that tolerance to the antiepileptic action does not develop. In the present paper, we describe the results of longterm treatment with VGB in 25 epileptic patients whose responsiveness to the drug had been demon-strated previously under placebo-controlled conditions. VGB, defined as an at least 50% reduction in seizure frequency or as a clinically important improvement in quality of life due to decreased seizure duration or severity. All the eligible patients fulfilling these criteria gave their consent to enter the study and were enrolled.
In 13 patients, previous response to VGB was established on the basis of the results of a double-blind randomised trial during which add-on VGB (2-3 g daily) and placebo were given for 7-week periods to a total of 20 patients.5 The remaining 12 patients were included after a 9-month singleblind study in 13 patients, which consisted of a 3-month baseline (I -month observation followed by 2 months placebo) and a subsequent 6-month period during which vigabatrin dosage (2-4 g daily) was adjusted according to clinical response.
Details of the patients included in the study are given in table 1. Study design Each patient was maintained on long-term treatment with VGB at a dosage up to 4 g daily (four 500 mg tablets b.i.d.) adjusted according to the clinical response. In nine patients, a VGB-free period of 11 days to 42 weeks (median 11 weeks) elapsed between the placebo-controlled evaluation and the start of long-term treatment. Twenty-four 467 
Results
Drop outs and duration offollow-up Eight patients dropped out of the study, one after 1 month because of ataxia (which rapidly subsided after discontinuation of VGB), one after 16 months because of psychotic symptoms, three after 6, 14 and 18 months because of seizure breakthrough and three after 4, 8 and 15 months for reasons unrelated to treatment. The duration of treatment in the 17 patients who continue on VGB ranges from 14 to 47 months (median 22 months). Efficacy data During the first two months of longterm VGB treatment, the median seizure frequency dropped to less than one half that observed during the placebo period and remained significantly reduced throughout the full duration of follow-up (fig 1) . Although the apparent improvement in seizure control after 2 years of follow-up reflects partly a bias effect related to a progressively decreasing number of patients, the persistence of seizure reduction during VGB therapy could be clearly confirmed by plotting separately the data from the 21 patients who received VGB for at least 14 consecutive months (fig 1, inset) . The persistence of the improved clinical control was also clearly apparent by examining the percent change Tartara The most frequently observed of these effects was weight gain, which ranged from 3 to 11 kg (5 to 16% of the initial body weight). With the exception of weight gain, which occurred usually after 3-6 months ofVGB therapy and tended to plateau within a few months, side effects were detected in a similar proportion of patients throughout the study. Only two patients discontinued VGB because of possibly drug-related adverse effects (ataxia and psychotic symptoms respectively) and only one patient required a reduction of VGB dosage because of suspected toxicity. Positive side effects (improved mood) were reported by four patients. Evoked patients before VGB8 and showed a trend towards normalisation during treatment. Serum anticonvulsant drug levels Before starting VGB, serum drug levels (jg/ml, means, s.d.) were 7-8, 2-7 for carbamazepine (n = 18), 28 7, 7-8 for phenobarbital (n = 16), 13-8, 4-2 for phenytoin (n = 5) and 48, 16 for valproic acid (n = 3). When all patients were considered together, mean serum carbamazepine, phenobarbital and valproic acid levels were not significantly affected by VGB, whereas serum phenytoin levels decreased significantly to 9 4, 4-2 jg/ml (p < 0-05). 
Discussion
For ethical reasons, only patients who had shown a clear-cut favorable response to VGB were selected for long-term treatment. Therefore, the study was not intended to assess the proportion ofpatients showing a satisfactory response but, rather, to obtain information on the risk/benefit ratio during maintenance therapy. At each study visit, the decision on whether to continue VGB was thoroughly discussed with each patient and treatment was maintained only when clinical data indicated significant therapeutic benefit. For this reason, the fact that 17 out of 25 patients are still on VGB after a period of up to 4 years is by itself an indication that the drug retained its efficacy. This conclusion is reinforced by the observation that only five patients dropped out because of possible adverse effects or seizure breakthrough. The persistent efficacy of VGB could be documented objectively by seizure frequency recording throughout follow-up. Compared with the placebo period, the mean percent reduction in seizure frequency after initial exposure to VGB (blind phase preceding follow-up) in these patients was 56, SD 29%. This compares with a mean reduction of 60, SD 29%, observed during the last 2 months of long-term therapy in the same subjects, including those who dropped-out. Although adjustments in VGB dosage were allowed during long-term therapy, the dosage of the drug during the last 2 months offollow-up (3 0, SD 0i8 g/day) was not markedly different from that used during the initial blind phase of the study (2-6, SD Vigabatrin in the treatment ofepilepsy: a long-term follow-up study 0-6 g/day). Moreover, changes in dosage were generally made during the first 14 months of treatment and overall seizure control showed no trend to deteriorate after this period (in fact, upwards dosage adjustments generally resulted in further improvement in fit frequency).
It might be argued that the sustained seizure control observed during long-term VGB could be partly related to a "regression towards the mean" phenomenon, but we feel that this is unlikely for at least two reasons. First, in almost half of the patients the initial response to VGB was assessed by using a double-blind design which included a randomised placebo-active drug sequence.4 Second, the depression of seizure frequency during VGB therapy was consistent throughout the long duration of follow-up (figs I and 2), without the relapses expected if the initial response was due to spontaneous variation in the severity of the seizure disorder.
Side effects were usually mild, the most frequent of them being weight gain. Possibly drug-related effects leading to VGB withdrawal were seen in only two cases. In the patient who developed ataxia after I month on VGB, the causative role of the drug is questionable because this subject had tolerated previously VGB for 7 
